Your Mid-Year Peptide Review: What's Working and What to Adjust

June is a strange little checkpoint. We're exactly halfway through the year, the New Year's resolutions are a distant memory, and most people I see have stopped paying close attention to whatever protocol they started back in January. That's a shame, because the six-month mark is honestly one of the most useful moments to take stock of peptide therapy. Long enough to see real signal. Early enough to course-correct before you've wasted another six months on something that isn't pulling its weight.

I'm Dr. Farhan Abdullah, and I run Magnolia Functional Wellness here in Southlake. A big chunk of my week is spent doing exactly this kind of review with patients, sitting down with their labs, their symptom logs, and their honest answers about whether they've actually been injecting four nights a week or quietly skipping half their doses. Peptides aren't magic. They're tools. And like any tool, they need to be checked, sharpened, and sometimes swapped out for a better one.

So let's do that. Consider this your mid-year peptide audit, the same framework I walk through in clinic, translated into something you can use to think critically about your own protocol.

Why the Six-Month Mark Matters More Than You Think

Here's something patients are often surprised to hear: a lot of peptides don't really declare themselves until month three, four, or five. People expect a switch to flip in week two. It almost never works that way.

Take the growth hormone secretagogues, the CJC-1295 and ipamorelin family that gets so much attention. These don't dump synthetic growth hormone into your bloodstream. They nudge your pituitary to release more of your own, in a pulsatile rhythm that mimics how a younger body behaves. That's a slower, gentler curve. The downstream marker we actually care about, IGF-1, climbs over weeks, not days. In one classic preclinical study published in Growth Hormone & IGF Research by Malmlöf and colleagues, repeated ipamorelin dosing produced measurable rises in IGF-1 alongside improved body composition, but those effects accumulated with consistent stimulation over time. A separate study by Aagaard and colleagues showed the same secretagogue could counteract steroid-driven muscle and protein breakdown, again as a gradual metabolic shift rather than an overnight one.

Both of those are animal studies, and I want to be straight with you about that, because honest framing matters when we talk about peptides. We don't have giant human trials on every compound in this space. What we do have is solid mechanistic data, decades of clinical use, and in some cases proper randomized trials. The point stands either way: the GH-axis peptides are a long game. If you started in January and you're judging them on how you felt in February, you measured the wrong thing at the wrong time. Mid-year, with a fresh IGF-1 draw in hand, is when the verdict actually means something.

What "Working" Actually Looks Like

This is where a lot of people get tripped up. They'll tell me a peptide "isn't doing anything," and when I dig in, it turns out they were chasing a feeling instead of tracking an outcome. Feelings are noisy. Outcomes are not.

So before you decide whether your protocol is earning its place, get specific about what you were trying to fix. The categories I use:

• Recovery and tissue healing. If you're running BPC-157 or a healing peptide for a cranky shoulder or a stubborn tendon, the question isn't "do I feel great." It's whether range of motion improved, whether the pain that used to flare after a workout now settles faster, whether you've needed less ibuprofen.
• Body composition. For the GH secretagogues, the scale is almost useless. Muscle is denser than fat. What you want is a DEXA scan, a tape measure at the waist, or even good photos in the same light every month. Are you leaner through the midsection? Recovering faster between training sessions? Sleeping more deeply?
• Energy, sleep, and cognition. Subjective, yes, but trackable if you write it down. A one-to-ten log beats a vague memory every single time.

The reason objective measurement matters so much here has a great real-world example in the growth hormone space. A 2014 randomized, double-blind, placebo-controlled trial published in JAMA by Stanley and colleagues tested tesamorelin, a GHRH analog peptide, against placebo over six months. The patients on tesamorelin lost a meaningful amount of visceral fat, the dangerous fat packed around the organs, with a net treatment effect of roughly 42 square centimeters on imaging compared to placebo. They also saw modest reductions in liver fat. Notice the timeline. Six months. And notice how they proved it, not by asking people how they felt, but with actual scans. That's the standard I want you holding your own protocol to. If we're optimizing the same GH axis with peptides at our peptide therapy program, we should be measuring with the same seriousness.

The Peptides Most Likely to Need Adjusting

Not every compound on your list is performing equally. In my experience, a few specific situations come up over and over at the mid-year check.

The GH secretagogue that plateaued

This is the most common one. Someone's been on CJC-1295/ipamorelin since winter, felt fantastic for the first couple of months, and now feels like the effect has flattened. Sometimes that's real receptor adaptation. Sometimes it's just that the dramatic early gains, better sleep, faster recovery, were the low-hanging fruit, and now you're in the maintenance phase where progress is quieter. The fix might be a brief cycling-off period, a dose timing change, or simply recalibrating expectations. It's rarely "abandon ship."

The healing peptide that finished its job

BPC-157 and similar repair peptides are, in my view, often meant to be temporary. You run them to heal a specific injury, the injury heals, and then you stop. If you're still injecting a tissue-repair peptide six months after the tendon stopped bothering you, that's not a protocol, that's a habit. Mid-year is a perfect time to ask: did this finish what it started? If yes, graduate off it.

The peptide you never gave a fair shot

And then there's the opposite problem. The person who started something promising, hit a busy stretch at work, started skipping doses, and now wants to declare it a failure. You can't fire an employee who never showed up. If consistency was the real issue, the honest move is to recommit for a defined window and then judge it. Half a protocol gives you half-answers.

When to Adjust, When to Cycle, and When to Walk Away

So how do you actually make the call? A few principles I lean on.

Adjust the dose or timing when the direction is right but the magnitude is underwhelming. Maybe your IGF-1 moved, but only a little, and you're tolerating the peptide well. That's a candidate for a thoughtful dose increase, ideally guided by repeat labs rather than guesswork. Maybe you've been dosing your GH secretagogue too close to a late meal, blunting the response, and a simple timing shift fixes it.

Cycle off when you suspect adaptation or you've hit a natural maintenance plateau. Many of these peptides perform better when the body isn't constantly stimulated. A planned break can restore sensitivity and, frankly, give your wallet a rest while you confirm whether you actually miss the effect.

Walk away when you've given a compound a genuine, consistent trial, measured it properly, and the needle simply didn't move. This is the decision people avoid most, because nobody likes admitting something didn't pan out. But a peptide that isn't delivering is just an expensive injection. There's no loyalty prize for sticking with something that doesn't work. Reallocating that effort and money toward something that does is the smart play, not a defeat.

What I'd caution against is making any of these moves blind. The whole advantage of working with a physician on peptide therapy is that you're adjusting based on data, your labs, your symptoms, your goals, not based on a forum post or what worked for some guy at the gym. Peptides interact with the rest of your physiology, including your hormones and metabolism, which is why I often look at the broader picture through the lens of longevity-focused medicine rather than treating any single compound in isolation.

How We Actually Run a Mid-Year Review

When a patient comes in for their six-month checkpoint at Magnolia, the visit follows a pretty consistent rhythm, and you can replicate a lighter version of it on your own.

First, we pull labs. For the GH-axis peptides that usually means IGF-1, plus a metabolic panel and often fasting glucose, since growth hormone signaling can nudge blood sugar. The tesamorelin trial I mentioned actually flagged a small early bump in fasting glucose that settled by six months, which is exactly the kind of thing you only catch if you're testing rather than assuming.

Second, we compare those numbers to baseline. Not to a textbook range, to your January starting point. Trends beat snapshots. A value sitting in the middle of the reference range can still represent a big personal improvement, or a quiet decline, depending on where you started.

Third, we go through the symptom log honestly. This is where the Southlake reality check happens. Between the kids' summer schedules, work travel, and the fact that nobody wants to inject anything in the middle of a June vacation, life gets in the way of protocols. If adherence slipped, we name it, and we factor it into the verdict instead of blaming the molecule.

Fourth, we decide together: continue, adjust, cycle, or stop, for each compound individually. Your stack is not a single yes-or-no decision. One peptide might be a keeper while another gets retired the same afternoon.

If there's one mindset I'd love you to take from all of this, it's that peptide therapy should be dynamic, not set-and-forget. The people who get the most out of it are the ones who treat it like a living protocol that gets pruned and refined a couple of times a year. Six months in is the perfect moment to do exactly that. Take an honest inventory, keep what's working, fix what's close, and let go of what isn't earning its place. If you'd like a second set of eyes on your protocol, that's the kind of conversation we have every week at Magnolia Functional Wellness here in Southlake, and the middle of the year is honestly the ideal time to have it.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX